SciELO - Scientific Electronic Library Online

vol.133 número3Anticuerpos antifosfolípidos en nefropatía membranosa idiopáticaSeropervalencia de la infección por virus herpes simplex tipo 2 en pacientes atendidos en centros de referencia de ETS de Santiago índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Revista médica de Chile

versión impresa ISSN 0034-9887


AFANI S, Alejandro et al. Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile. Rev. méd. Chile [online]. 2005, vol.133, n.3, pp.295-301. ISSN 0034-9887.

Background: Resistance to antiretroviral therapy is a determining factor for therapeutic failure in HIV/AIDS. The prevalence of primary resistance (i.e. in those patients that have not received treatment) varies in different parts of the world. Aim: To study the prevalence of primary resistance to antiretroviral drugs in patients living in Northern Santiago. Patients and methods: Viral load, lymphocyte subpopulations by flow cytometry and genotypic resistance testing were assessed in blood samples from 60 HIV-1 infected patients (mean age 37 years, 54 male). Results: Mean CD4 cell count and viral load was 200 cells/ml and 142,840 RNA copies/ml respectively. Ten mutations were identified: V179D, L10I/V, M361, L63P, A71T/V, Y115F, V118I and K20R. None of these mutations is associated to a high degree of resistance to reverse transcriptase inhibitors, nucleoside analogs (NRTI), non nucleoside analogs (NNRTI) or viral protease inhibitors. Conclusions: This is a first approach to study antiretroviral resistance in Chilean patients. This study must be amplified, since the prevalence of resistance may experience changes with time (Rev Méd Chile 2005; 133: 295-301)

Palabras clave : Acquired immunodeficiency syndrome; Antiretroviral therapy, highly active; HIV infections.

        · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons